Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6151568 | 0.91 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL6151610 | 0.87 | EDNRA (0.89) | EDNRAEDNRB | |
| SCHEMBL6151615 | 0.87 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL9063334 | 0.87 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL4631503 | 0.87 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL6151645 | 0.86 | EDNRA (0.86) | EDNRAEDNRB | |
| SCHEMBL6151368 | 0.85 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL27548681 | 0.84 | EDNRA (0.71) | EDNRAEDNRB | |
| SCHEMBL6151584 | 0.84 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL4630630 | 0.83 | EDNRA (1.00) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0980369-B1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | ENCYSIVE PHARMACEUTICALS INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1498418-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1498419-A1 | Process for preparing alkali metal salts of hydrophobic sulfonamides | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-0946552-B1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | ENCYSIVE PHARMACEUTICALS INC (US) | 2004-07-07 | — | — | EP | disclosed |